➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Mallinckrodt
Harvard Business School
Dow

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

MIDAZOLAM IN 0.9% SODIUM CHLORIDE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Midazolam In 0.9% Sodium Chloride, and what generic alternatives are available?

Midazolam In 0.9% Sodium Chloride is a drug marketed by Inforlife and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in MIDAZOLAM IN 0.9% SODIUM CHLORIDE is midazolam. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the midazolam profile page.

DrugPatentWatch® Generic Entry Outlook for Midazolam In 0.9% Sodium Chloride

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 20, 2038. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (midazolam), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Drug patent expirations by year for MIDAZOLAM IN 0.9% SODIUM CHLORIDE
DrugPatentWatch® Estimated Generic Entry Opportunity Date for MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Generic Entry Date for MIDAZOLAM IN 0.9% SODIUM CHLORIDE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MIDAZOLAM IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brigham and Women's HospitalN/A
United States Department of DefenseN/A
The Geneva FoundationN/A

See all MIDAZOLAM IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Drug ClassBenzodiazepine
Anatomical Therapeutic Chemical (ATC) Classes for MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Paragraph IV (Patent) Challenges for MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
MIDAZOLAM IN 0.9% SODIUM CHLORIDE SOLUTION;INTRAVENOUS midazolam 211844 2021-09-29

US Patents and Regulatory Information for MIDAZOLAM IN 0.9% SODIUM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Inforlife MIDAZOLAM IN 0.9% SODIUM CHLORIDE midazolam SOLUTION;INTRAVENOUS 211844-001 Mar 22, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Inforlife MIDAZOLAM IN 0.9% SODIUM CHLORIDE midazolam SOLUTION;INTRAVENOUS 211844-002 Mar 22, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Mallinckrodt
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.